A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
Phase 2
Suspended
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: 0.075 mg RVX-100Drug: 0.125 mg RVX-100Drug: 0.250 mg RVX-100Drug: placebo
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Revogenex, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT01076699
- Locations
- 🇺🇸
Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath